Safety and efficacy of biosimilars in oncology.

Safety and efficacy of biosimilars in oncology.

Item
http://www.wikidata.org/entity/Q39000625
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesAn introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Technologies and strategies for bioanalysis of biopharmaceuticals.Rituximab biosimilar evaluated by network meta-analysis.Biosimilar monoclonal antibodies (mAbs) in oncology.Identification and validation a TGF-β-associated long non-coding RNA of head and neck squamous cell carcinoma by bioinformatics method.Development and 10-year history of a biosimilar: the example of Binocrit®.Integrating Biosimilars Into Oncology Practice: Implications for the Advanced PractitionerComment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"
P2860

Safety and efficacy of biosimilars in oncology.

Item
http://www.wikidata.org/entity/Q39000625
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Safety and efficacy of biosimilars in oncology.
@en
Safety and efficacy of biosimilars in oncology.
@nl
type
label
Safety and efficacy of biosimilars in oncology.
@en
Safety and efficacy of biosimilars in oncology.
@nl
prefLabel
Safety and efficacy of biosimilars in oncology.
@en
Safety and efficacy of biosimilars in oncology.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Safety and efficacy of biosimilars in oncology.
@en
P2093
P304
P31
P356
10.1016/S1470-2045(16)30374-6
P433
P478
P50
P577
P698